Biondvax Pharmaceuticals PEG Ratio

Biondvax Pharmaceuticals's peg ratio stands at 30.16. That is above the Healthcare sector average of 11.64. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Biondvax Pharmaceuticals sits higher the Healthcare benchmark (11.64) with a PEG ratio of 30.16. That is roughly 159.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 30.16 is attractive depends on Biondvax Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Biondvax Pharmaceuticals's PEG ratio evolved across reporting periods, while the comparison chart places BVXV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Biondvax Pharmaceuticals's reading of 30.16 (sector avg 11.64) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.